Patients with tumors in the trigone and urethra were more likely to experience recurrence and cancer-specific death after radical cystectomy than patients with tumor only in the bladder walls.

Trigone Pharma, a pharmaceutical company dedicated to developing novel solutions that treat bladder cancers and urologic diseases, and 4C Biomed, an early-stage biomed R&D group specializing in ...

(a) 3D remodeling of the whole specimen (ureter, bladder, trigone of bladder, ductus deferens, prostate and seminal gland, ejaculatory duct, external urethral sphincter, neurovascular structures).

TRG-100 is now being evaluated in broad range of bladder disordersRAANANA, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma Ltd. a leader in the field of urological diseases, today ...

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.